XIAN Zong-shu, LI Guang-hui, GAI Jun-wei, ZHU Min, MA Lin-lin, JU Dian-wen, WAN Ya-kun. The screening and identification of internalized nanobody against EpCAM J. Acta Pharmaceutica Sinica, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359
Citation: XIAN Zong-shu, LI Guang-hui, GAI Jun-wei, ZHU Min, MA Lin-lin, JU Dian-wen, WAN Ya-kun. The screening and identification of internalized nanobody against EpCAM J. Acta Pharmaceutica Sinica, 2020,55(10): 2405-2413. doi: 10.16438/j.0513-4870.2020-1359

The screening and identification of internalized nanobody against EpCAM

  • Epithelial cell adhesion molecule (EpCAM) is a popular target for cancer therapy. In this research, 3 nanobodies with high specificity and endocytosis activity against EpCAM were developed, which provides a basis for the study of immunotoxin based on EpCAM. In our preliminary experiments, we have immunized a camel with EpCAM-Fc antigen and constructed a high-quality phage display library. Seventeen nanobodies with different complementarity determining region (CDR) 3 sequences have been screened after 3 rounds of biopanning by phage display technology. The animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Fudan University School of Pharmacy. After purification, 7 nanobodies showed high cell binding activity by fluorescent activated cell sorting (FACS) identification. Furthermore, 3 nanobodies presented high endocytosis activity based on FACS and laser confocal microscopy, which also showed high affinity to EpCAM measured by ForteBio. According to this study, we aimed to provide a novel alternative approach to the EpCAM-targeted therapy and to provide guidance for the study of nanobody based immunotoxins for other targets.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return